{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$4.92 vs. cons $4.79",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.78B vs. cons $3.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diagnostics organic revenue growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~+5.5% vs. cons ~+4.5%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Adjusted EPS guide",
      "prediction": "BETTER",
      "answer": "guide ~$17.90-$18.55 (mid ~$18.23) vs. cons ~$18.05 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Enterprise revenue guide",
      "prediction": "BETTER",
      "answer": "guide ~$14.75-$14.95B (mid ~$14.85B) vs. cons ~$14.78B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BLS book-to-bill inflection",
      "prediction": "BETTER",
      "answer": "pred ~1.02 vs. 0.94 prior quarter (Q2 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY26 Free cash flow guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~$1.24-$1.36B vs. cons ~$1.30B (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -5.0,
  "day5_path": "FADE",
  "day5_rationale": "LH ripped ~13% in two weeks (and ~+45% off June lows) almost entirely on Quest read-through, so a beat-and-raise is largely priced; realized beta to SPX is ~0 (idiosyncratic move), meaning residual \u2248 raw. Even with a clean beat, guide raise quality is modest (Q1 flow-through + FX) and the 2027 PAMA/RESULTS/CRUSH/ACA-subsidy overhang caps upward out-period revisions ahead of the Sept 10 Investor Day. Crowded long unwinds into a 'sell-the-news' \u2014 initial day-1 drop extends as estimates stabilize rather than ratchet higher.",
  "day5_confidence": "LOW"
}